BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

China Grants First Approval for Tzield to Delay Onset of Type 1 Diabetes

Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the onset of stage 3 T1D in adult and pediatric patients aged eight year...

September 11, 2025 | News

XtalPi and PharmaEngine Advance AI-Designed PRMT5 Inhibitor PEP08 into Phase 1 Trials for Solid Tumours

XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaborati...

September 10, 2025 | News

iRegene Secures Over RMB 300 Million in Landmark Series B+ Financing to Advance First-in-Class iPSC Cell Therapies

iRegene Therapeutics (Chengdu) Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, ...

September 10, 2025 | News

Metabolon Partners with China Kadoorie Biobank to Advance Landmark Multiomics Study on Common Diseases

The landmark multiomics study will examine how lifestyle, environmental, socioeconomic, and genetic factors play a significant role in shaping common disea...

September 10, 2025 | News

The State of Biotech and Life Science Jobs in Asia Pacific – 2025

In 2025, Asia-Pacific has emerged as the fastest-growing hub for biotech and life sciences employment, fuelled by a powerful combination of government supp...

September 09, 2025 | Report

Epigenic Therapeutics Raises $60 Million in Series B Financing to Advance Epigenetic Medicine Pipeline

Epigenic Therapeutics ("Epigenic"), a clinical-stage innovative drug development company, today announced the completion of a $60 million Series ...

September 09, 2025 | News

Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025

In 2025, sustainable innovation has become a core focus in biotechnology and biopharmaceutical industries worldwide. Private companies are at the forefront...

September 08, 2025 | Analysis

Huadong Medicine Reports Promising Phase I Results for Novel ROR1-Targeting ADC HDM2005 in Lymphoma

Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") announced positive preliminary results from a Phase I study of HDM2005, an...

September 08, 2025 | News

Stallergenes Greer and Nuance Pharma Enter Exclusive Partnership to Develop and Commercialise Actair® in China

Stallergenes Greer, a global leader in allergy therapeutics, and Nuance Pharma, an innovation-focused biopharmaceutical company based in China, announced t...

September 05, 2025 | News

China’s Biocytogen and Germany’s Merck KGaA Join Forces on Antibody-LNP Delivery Innovation

-Biocytogen Pharmaceuticals , a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative te...

September 05, 2025 | News

FDA Approves Henlius and Organon’s Denosumab Biosimilars BILDYOS and BILPREVDA for All US Indications

Shanghai Henlius Biotech, Inc. and Organon announced that the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) inject...

September 04, 2025 | News

China’s Akeso Completes Phase III Enrollment for Ivonescimab in Advanced Biliary Tract Cancer

Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study eva...

September 03, 2025 | News

China’s Bon Natural Life Unveils Tea-Derived Compounds for Weight Management Through AI-Powered Drug Discovery

Bon Natural Life Limited , a leading bio-ingredient solution provider in the natural, health and personal care industry, announced a groundbreaking identif...

September 03, 2025 | News

Alphamab Oncology Reports Strong H1 2025 Growth and Pipeline Advancements, Achieving Profitability

Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months ended June 30, 2025 and highlighted recent business...

September 01, 2025 | Company results

Stay Connected